In both metazoan development and metastatic cancer, migrating cells must carry out a detailed, complex program of sensing cues, binding substrates, and moving their cytoskeletons. The linker cell in Caenorhabditis elegans males undergoes a stereotyped migration that guides gonad organogenesis, occurs with precise timing, and requires the nuclear hormone receptor NHR-67. To better understand how this occurs, we performed RNA-seq of individually staged and dissected linker cells, comparing transcriptomes from linker cells of third-stage (L3) larvae, fourth-stage (L4) larvae, and nhr-67-RNAi–treated L4 larvae. We observed expression of 8,000–10,000 genes in the linker cell, 22–25% of which were up- or down-regulated 20-fold during development by NHR-67. Of genes that we tested by RNAi, 22% (45 of 204) were required for normal shape and migration, suggesting that many NHR-67–dependent, linker cell-enriched genes play roles in this migration. One unexpected class of genes up-regulated by NHR-67 was tandem pore potassium channels, which are required for normal linker-cell migration. We also found phenotypes for genes with human orthologs but no previously described migratory function. Our results provide an extensive catalog of genes that act in a migrating cell, identify unique molecular functions involved in nematode cell migration, and suggest similar functions in humans.

https://science.sciencemag.org/content/sci/256/5054/184.full.pdf

Alzheimer's disease: the amyloid cascade hypothesis

Rapid progress in deciphering the biological mechanism of Alzheimer's disease (AD) has arisen from the application of molecular and cell biology to this complex disorder of the limbic and association cortices. In turn, new insights into fundamental aspects of protein biology have resulted from research on the disease. This beneficial interplay between basic and applied cell biology is well illustrated by advances in understanding the genotype-to-phenotype relationships of familial Alzheimer's disease. All four genes definitively linked to inherited forms of the disease to date have been shown to increase the production and/or deposition of amyloid β-protein in the brain. In particular, evidence that the presenilin proteins, mutations in which cause the most aggressive form of inherited AD, lead to altered intramembranous cleavage of the β-amyloid precursor protein by the protease called γ-secretase has spurred progress toward novel therapeutics. The finding that presenilin itself may be the long-sought γ-...

Alzheimer's Disease: Genes, Proteins, and Therapy

The molecular pathology of Alzheimer's disease.

Amyloid deposition as the central event in the aetiology of Alzheimer's disease

Converging lines of evidence suggest that progressive accumulation of the amyloid beta-protein (A beta) plays a central role in the genesis of Alzheimer's disease, but it was long assumed that A beta had to be assembled into extracellular amyloid fibrils to exert its cytotoxic effects. Over the past decade, data have emerged from the use of synthetic A beta peptides, cell culture models, beta-amyloid precursor protein transgenic mice and human brain to suggest that pre-fibrillar, diffusible assemblies of A beta are also deleterious. Although the precise molecular identity of these soluble toxins remains unsettled, accumulating evidence suggests that soluble forms of A beta are indeed the proximate effectors of synapse loss and neuronal injury. Here we review recent progress in understanding the role of soluble oligomers in Alzheimer's disease.

https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1471-4159.2006.04426.x

A beta oligomers - a decade of discovery.

https://www.cell.com/cell/pdf/0092-8674(89)90177-3.pdf

Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein

The promoter of the gene for the human precursor of Alzheimer's disease A4 amyloid protein (PAD gene) resembles promoters of housekeeping genes. It lacks a typical TATA box and shows a high GC content of 72% in a DNA region that confers promoter activity to a reporter gene in an in vivo assay. Transcription initiates at multiple sites. Sequences homologous to the consensus binding sites of transcription factor AP-1 and the heat shock control element binding protein were found upstream of the RNA start sites. Six copies of a 9-bp-long GC-rich element are located between positions -200 and -100. A protein--DNA interaction could be mapped to this element. The 3.8 kb of the 5' region of the PAD gene include two Alu-type repetitive sequences. These findings suggest that four mechanisms may participate in the regulation of the PAD gene and could be of relevance for the progression of amyloid deposition in Alzheimer's disease.

Promoter of alzheimer??s disease amyloid a4 precursor gene

The precursor of the Alzheimer's disease‐specific amyloid A4 protein is an integral, glycosylated membrane protein which spans the bilayer once. The carboxy‐terminal domain of 47 residues was located at the cytoplasmic site of the membrane. The three domains following the transient signal sequence of 17 residues face the opposite side of the membrane. The C‐terminal 100 residues of the precursor comprising the amyloid A4 part and the cytoplasmic domain have a high tendency to aggregate, and proteinase K treatment results in peptides of the size of amyloid A4. This finding suggests that there is a precursor‐product relationship between precursor and amyloid A4 and we conclude that besides proteolytic cleavage other events such as post‐translational modification and membrane injury are primary events that precede the release of the small aggregating amyloid A4 subunit.

Identification, transmembrane orientation andbiogenesis oftheamyloid A4 precursorofAlzheimer's disease

Molecular pathology of the amyloid a4 precursor of alzheimer??s disease

Alzheimer’s disease (AD) is a progressive degenerative disorder of the human central nervous system. The prominent pathological marker is the accumulation of intracellular and extracellular amyloid deposits in the brain. The major protein component of these amyloid depositions is the sA4 protein, termed according to it’s proposed secondary structure of beta pleated sheets, and it’s molecular weight of 4kD. Protein sequence analysis of amyloid deposits isolated either from brains of patients with AD or from brains of aged individuals with Down’s syndrome (DS) revealed the sA4 protein to consist of 42–43 residues (Glenner and Wong, 1984; Masters et al., 1985a, b; Kang et al., 1987). Amyloidogenesis in AD and DS is accompanied by neuronal dysfunction, reduced synaptic density, gliosis, and neuronal loss (Muller-Hill and Beyreuther, 1989). Some of these changes, including amyloid plaques are also observed in the normal aging process, however to a much lesser extent (Rumble et al., 1989).

J. Michael Salbaum

Papers

Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein

Promoter of alzheimer??s disease amyloid a4 precursor gene

Identification, transmembrane orientation andbiogenesis oftheamyloid A4 precursorofAlzheimer's disease

Molecular pathology of the amyloid a4 precursor of alzheimer??s disease

Regulation of the Amyloid Gene of Alzheimer’s Disease